October 10, 2019
The Ministry of Health, Labor and Welfare (MHLW) plans to set up a new medical fee schedule for the treatment of renal anemia with the soon-to-come launch of Astellas Pharma’s hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor approved last month. The...read more